Comparison of the in-vivo muscarinic cholinergic receptor availability in patients treated with clozapine and olanzapine

International Journal of Neuropsychopharmacology

Volumn 10, Issue 2, 2007, Pages 275-280

  Raedler, Thomas J ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Clozapine; IQNB; Muscarinic receptors; Olanzapine; Schizophrenia; SPECT

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; MUSCARINIC RECEPTOR; OLANZAPINE; QUINUCLIDINYL BENZILATE; QUINUCLIDINYL BENZILATE I 123; RADIOISOTOPE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BASAL GANGLION; BRAIN CORTEX; BRAIN REGION; CLINICAL ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG RECEPTOR BINDING; FEMALE; HUMAN; MALE; PONS; PRIORITY JOURNAL; RECEPTOR BLOCKING; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THALAMUS;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BRAIN CHEMISTRY; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; QUINUCLIDINYL BENZILATE; RADIOPHARMACEUTICALS; RECEPTORS, MUSCARINIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 33847053999     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145706006584     Document Type: Article

References (33)

1. Beasley CM, Hamilton SH, Crawford AM, Dellva MA, Tollefson GD, Tran PV, Blin O, Beuzen JN (1997). Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. European Neuropsychopharmacology 7, 125-137.
2. Beasley CM, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S (1996). Olanzapine versus placebo: results of a double-blind, fixed-dosed olanzapine trial. Psychopharmacology 124, 159-167.
3. Bolden C, Cusack B, Richelson E (1992). Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. Journal of Pharmacology and Experimental Therapeutics 260, 576-580.
4. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT (1996). Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14, 87-96.
5. Bymaster FP, Falcone JF (2000). Decreased binding affinity of olanzapine and clozapine for human muscarinic receptors in intact clonal cells in physiological medium. European Journal of Pharmacology 390, 245-248.
6. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO (1999). Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophrenia Research 37, 107-122.
7. Chengappa KN, Pollock BG, Parepally H, Levine J, Kirshner MA, Brar JS, Zoretich RA (2000). Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine. Journal of Clinical Psychopharmacology 20, 311-316.
8. Conley RR, Tamminga CA, Kelly DL, Richardson CM (1999). Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. Biological Psychiatry 46, 73-77.
9. Davies MA, Compton-Toth BA, Hufeisen SJ, Meltzer HY, Roth BL (2005). The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions? Psychopharmacology 178, 451-460.
10. Gonul AS, Kula M, Sofuoglu S, Tutus A, Esel E (2003). Tc-99 HMPAO SPECT study of regional cerebral blood flow in olanzapine-treated schizophrenic patients. European Archives of Psychiatry and Clinical Neuroscience 253, 29-33.
11. Kane JM, Honigfeld G, Singer J, Meltzer HY (1988). Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry 45, 789-796.
12. Kapur S, Barlow K, VanderSpek SC, Javanmard M, Nobrega JN (2001). Drug-induced receptor occupancy: substantial differences in measurements made in vivo vs. ex vivo. Psychopharmacology 157, 168-171.
13. 123I]IDEX SPECT study. Psychopharmacology 156, 53-57.
14. Littrell KH, Johnson CG, Hilligoss NM, Peabody CD, Littrell SH (2000). Switching clozapine responders to olanzapine. Journal of Clinical Psychiatry 61, 912-915.
15. 4 subtypes of muscarinic receptors. European Journal of Pharmacology 376, 119-125.
16. Molina Rodriguez V, Montz Andreé R, Pérez Castejón MJ, Capdevila Garcia E, Carreras Delgado JL, Rubia Vila FJ (1996). SPECT study of regional cerebral perfusion in neuroleptic-resistant schizophrenic patients who responded or did not respond to clozapine. American Journal of Psychiatry 153, 1343-1346.
17. Mulsant BH, Gharabawi GM, Bossie CA, Mao L, Martinez RA, Tune LE, Greenspan AJ, Bastean JN, Pollock BG (2004). Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine. Journal of Clinical Psychiatry 65, 1708-1714.
18. 123I]-I-QNB: methodological considerations. Nuclear Medicine and Biology 31, 583-590.
19. Olianas MC, Maullu C, Onali P (1999). Mixed agonistantagonist properties of clozapine at different human cloned muscarinic receptor subtypes expressed in Chinese hamster ovary cells. Neuropsychopharmacology 20, 263-270.
20. Raedler TJ, Knable MB, Jones DW, Egan MF, Weinberger DR (2003). Central muscarinic acetylcholine receptor availability in patients treated with clozapine. Neuropsychopharmacology 28, 1531-1537.
21. Raedler TJ, Knable MB, Jones DW, Lafargue T, Urbina RA, Egan MF, Pickar D, Weinberger DR (2000). In vivo olanzapine occupancy of muscarinic acetylcholine receptors in patients with schizophrenia. Neuropsychopharmacology 23, 56-68.
22. Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, Fye C, Charney D (1997). A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. New England Journal of Medicine 337, 809-815.
23. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE (1996). Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124, 57-73.
24. Sur C, Mallorga PJ, Wittmann M, Jacobson MA, Pascarella D, Williams JB, Brandish PE, Pettibone DJ, Scolnick EM, Conn PJ (2003). N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proceedings of the National Academy of Sciences, USA 100, 13674-13679.
25. Tollefson GD, Beasley Jr. CM, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME (1997a). Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry 154, 457-465.
26. Tollefson GD, Beasley CM, Tamura RN, Tran PV, Potvin JH (1997b). Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. American Journal of Psychiatry 154, 1248-1254.
27. Tollefson GD, Birkett MA, Kiesler GM, Wood AJ, Lilly Resistant Schizophrenia Study Group (2001). Doubleblind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biological Psychiatry 49, 52-63.
28. Tran PV, Dellva MA, Tollefson GD, Beasley CM, Potvin JH, Kiesler GM (1997). Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. Journal of Clinical Psychiatry 58, 205-211.
29. Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Cooper TB, Chakos M, Lieberman JA (2002). Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. American Journal of Psychiatry 159, 255-262.
30. Weiner DM, Meltzer HY, Veinbergs I, Donohue EM, Spalding TA, Smith TT, Mohell N, Harvey SC, Lameh J, Nash N, et al. (2004). The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology 177, 207-216.
31. 4 receptor activation by some atypical antipsychotic drugs. European Journal of Pharmacology 321, 349-354.
32. Zhang W, Bymaster FP (1999). The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors. Psychopharmacology 141, 267-278.
33. 4 receptor agonist. European Journal of Pharmacology 269, R1-R2.